Diagnostics
CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as…
Read More
BioFluidica LiquidScan Next-Generation Testing Platform, Can Detect Diseases in 15 Minutes Excerpt from the Press Release: SAN DIEGO, March 23, 2022 /PRNewswire/ — BioFluidica, a privately held biotechnology company, today announced they have been awarded a continuation grant from the Midwest Biomedical Accelerator Research Consortium (MBArC) on behalf of the National Institutes of Health Rapid Acceleration of…
Read More
Thermo Fisher Scientific to Support National Program to Accelerate SARS-CoV-2 Variant Identification
Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as…
Read More
Excerpt from the Press Release: BOSTON & CLEVELAND–(BUSINESS WIRE)–PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Cleveland Clinic today announced a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas. This collaborative effort combines…
Read More
Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®. In a real-world analysis of 1,076…
Read More
Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates…
Read More
Excerpt from the Press Release: PLEASANTON, Calif., Jan. 5, 2022 /PRNewswire/ — DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on…
Read More
Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Excerpt from the Press Release: Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company developing novel oncology therapeutics…
Read More
COVISTIX maintains its ability to detect the Omicron Variant, in addition to detecting SARS-CoV-2 and all of its major variants of concern (VoCs); COVISTIX has the potential to be a “Best-in-Class” rapid COVID-19 virus antigen detection test: Comparative studies with all available EUA-approved COVID-19 virus rapid antigen detection tests demonstrated that COVISTIX significantly outperforms in…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19…
Read More